Dr. Alexander Wyatt keynote at New Investigator Clinical Trials Course

Dr. Alexander Wyatt keynote speaker: New Investigator Clinical Trials Course

The CCTG New Investigator Clinical Trials Course is fast approaching and has already reached the maximum registration. The course will be held August 3 – 5, 2022 in Kingston, Ontario to provide and facilitate investigator education and training designed to educate new investigators from across the country about the essentials of clinical trial conduct in the Canadian research environment.

More >>
 

Matching ExCELLirate Canada funding from The Ontario Research Fund

It was recently announced that ExCELLirate Canada has successfully been granted a Research Infrastructure award of $4,159,049 by the Ontario Research Fund for the Innovation Fund Project Grant "ExCELLirate Canada: Expanding CELL-based Immunotherapy Research Acceleration for Translation and Evaluation".

More >>
 

CCTG at ASCO 2022

CCTG trials that were featured at the American Society of Clinical Oncology General Meeting 2022 June 3-7, 2022 – McCormick Place, Chicago

More >>
 

CCTG MA32 trial was published recently in the Journal of the American Medical Association

The findings of the CCTG MA32 trial were published recently in the Journal of the American Me

More >>
 

Planned trials

AL6

MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML

ALC7

Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH clinical trials

ALC8

Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)

ALC9

Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)

BLC5

MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer

More >>

BR37

Phase II Pre-operative Platform Trial in Surgically Resectable NSCLC

EN10

Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)

GA4

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

HD12

PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)

HN11

SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)

More >>

HN12

PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)

HN13

Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)

MA41

De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)

NE1

NET RETREAT: 177Lutetium- DOTATATE Retreatment vs. Everolimus in Metastatic/unresectable Midgut NET

PR23

Evaluating the Impact of SBRT with or without Nirapariib in Metastatic Hormone Sensitive Prostate Cancer Treated with ADT and Androgen Axis Directed Therapy

SC28

The SEEMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS

PR25

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes

CRC10

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

BR37A

A Phase II Pre-operative Trial of JDQ433 in Surgically Resectable NSCLC

MA32R

Late Recurrence Substudy of A Phase III Randomized Trial of Metformin vs Placebo on Recurrence and Surivival in Early-Stage Breast Cancer

Recently activated

CLC3E

Economic Analysis of Early vs Delayed Therapy in Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

More >>

HD11

Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

More >>

MAC27

COMPASSHER2 Residual Disease, A Double-Blinded, Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

More >>

MEC6

Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Muscosal Melanoma

More >>

MYC2

Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC)

More >>

PAC4

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

More >>

Fighting a rare battle

Cancer is not a single disease; it is hundreds. Cancers of the lung, breast, prostate, and colon are the most common forms of the disease, and account for about half of all diagnoses. But less common forms of cancer also account for about half of diagnoses, and these are not as well studied.

More >>
 
The Impact of the COVID-19 on Canadians Living with Cancer

CCTG SC27 - The Impact of the COVID-19 on Canadians Living with Cancer

CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.

More >>
 

Asking the right questions

Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.  

“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 

Publications

Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

Translational Lung Cancer Research 10: 826 - 838, 21 F
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;

More >>

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Nature Communications 13: 3607 - 3619, 2022
Hilton J;Gelmon K;Bedard PL;Tu D;Xu H;Tinker AV;Goodwin R;Laurie SA;Jonker D;Hansen AR;Veitch ZW;Renouf DJ;Hagerman L;Lui H;Chen B;Kellar D;Li I;Lee SE;Kono T;Cheng BYC;Yap D;Lai D;Beatty S;Soong J;Pritchard KI;Soria-Bretones I;Chen E;Feilotter H;Rushton M;Seymour L;Aparicio S;Cescon DW;

More >>

Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial

J Clin Oncol 40: 9046 - 9046, 2022
Parra ER;Duose DY;Zhang J;Redman MW;Lazcano Segura R;Marques-Piubelli ML;Laberiano Fernandez C;Zhang B;Lindsay J;Moravec R;Kannan K;Luthra R;Alatrash G;Herbst RS;Wistuba II;Gettinger SN;Bazhenova L;Lee JJ;Zhang J;Haymaker CL;

More >>

Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab +/- ipilimumab

J Clin Oncol 40: 9044 - 9044, 2022
Gonzalez-Kozlova E;Huang HH;Redman MW;Herbst RS;Gettinger SN;Bazhenova L;Xie H;Patel M;Nie K;Harris J;Argueta K;Cerami E;Hong J;Biswas R;Van Nostrand S;Kelly K;Moravec R;Del Valle D;Kim-Schulze S;Gnjatic S;

More >>

Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP)

J Clin Oncol 40: 6543 - 6543, 2022
Vaidya R;Unger JM;Qian L;Minichiello K;Herbst RS;Gandara DR;Neal JW;Leal T;Patel JD;Dragnev KH;Waqar SN;Edelman MJ;Sigal EV;Adam S;Malik SM;Blanke CD;LeBlanc ML;Kelly K;Redman MW;

More >>

Effect of bone metastasis on outcomes in the CCTG BR.34 phase II randomized trial of dual immune checkpoint inhibitor (ICI) treatment with or without chemotherapy in high-risk, stage IVA/B NSCLC

J Clin Oncol 40: 9067 - 9067, 2022
Leitzel K;Ali SM;Ding K;Leighl NB;Vera Badillo FE;Gaudreau PO;Bradbury PA;Goss GD;Shepherd LE;Costa L;Suva LJ;Drabick JJ;Ma PC;Joshi M;Polimera HV;Lipton A;

More >>

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001)

J Clin Oncol 40: TPS4607 - TPS4607, 2022
Gupta S;Ballman KV;Galsky MD;Morris MJ;Chen RC;Chan TA;Dercle L;Wen Y;Sridhar SS;Yen AE;Grivas P;Tan A;Baghaie S;Rosenberg JE;

More >>